Cited by 1,233Multiple Myeloma Research and TreatmentsBone health and treatmentsProtein Degradation and Inhibitors

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America

Open access

Weber, Donna M., Chen, Christine, Niesvizky, Ruben, Wang, Michael, Belch, Andrew, Stadtmauer, Edward A., Siegel, David, Borrello, Ivan, Rajkumar, S. Vincent, Chanan-Khan, Asher Alban, Lonial, Sagar, Yu, Zhinuan, Patin, John, Olesnyckyj, Marta, Zeldis, Jerome B., Knight, Robert D.·2007·New England Journal of Medicine

DOI 10.1056/nejmoa070596

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Lenalidomide, an oral immunomodulatory drug that is similar to thalidomide but has a different safety profile, has clinical activity in relapsed or refractory multiple myeloma. METHODS: Patients in the United States and Canada who had received at least one previous therapy for multiple myeloma but who required additional treatment were randomly assigned to receive either 25 mg of lenalidomide or placebo on days 1 to 21 of a 28-day cycle. Both groups also received 40 mg of oral dexamethasone on days 1 to 4, 9 to 12, and 17 to 20 for the first four cycles. After the fourth cycle, 40 mg of dexamethasone was administered only on days 1 to 4. Safety, clinical response, time to progression, and overall survival were assessed. RESULTS: We assigned 177 patients to the lenalidomide group and 176 to the placebo group. Complete, near-complete, or partial responses occurred in 108 patients (61.0%) in the lenalidomide group and in 35 patients (19.9%) in the placebo group (P<0.001); complete responses occurred in 14.1% and 0.6%, respectively (P<0.001). The median time to progression was 11.1 months in the lenalidomide group and 4.7 months in the placebo group (P<0.001). Median overall survival times in the two groups were 29.6 months and 20.2 months, respectively (P<0.001). Grade 3 or 4 adverse events were reported in 85.3% of the lenalidomide group and in 73.1% of the placebo group; these events resulted in study discontinuation in 19.8% and 10.2%, respectively. Grade 3 or 4 neutropenia and venous thromboembolism were more common in the lenalidomide group than in the placebo group (41.2% vs. 4.6% and 14.7% vs. 3.4%, respectively; P<0.001 for both comparisons). CONCLUSIONS: Lenalidomide plus dexamethasone is superior to placebo plus dexamethasone in patients with relapsed or refractory multiple myeloma. (ClinicalTrials.gov number, NCT00056160 [ClinicalTrials.gov].).

Integrity signals

Registry

Crossref · 10.1056/nejmoa070596

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Self-citation
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Self-citation
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G. G., Sonneveld, P., Schuster, M. W., Irwin, D. H., Stadtmauer, E. A., Facon, T. T. F., Harousseau, J., Ben‐Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,512
Self-citation
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
Bladé, J., Samson, D., Reece, D. E., Apperley, J. F., Björkstrand, B., Gahrton, G., Gertz, M. A., Giralt, S. A., Jagannath, S., & Vesole, D. H. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,516
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
Hideshima, T., Chauhan, D., Shima, Y., Raje, N. S., Davies, F. E., Tai, Y., Treon, S. P., Lin, B. K., Schlossman, R. L., Richardson, P. G. G., et al. (2000) · Blood · doi:10.1182/blood.v96.9.2943 · Cited by 874
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0996 · Cited by 804
Self-citation
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
Rajkumar, S. V., Hayman, S. R., Lacy, M. Q., Dispenzieri, A., Geyer, S. M., Kabat, B., Zeldenrust, S. R., Kumar, S., Greipp, P. R., Fonseca, R., et al. (2005) · Blood · doi:10.1182/blood-2005-07-2817 · Cited by 648
Self-citation
Thalidomide Alone or With Dexamethasone for Previously Untreated Multiple Myeloma
Weber, D., Rankin, K., Gavino, M., Delasalle, K. B., & Alexanian, R. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.139 · Cited by 565
Self-citation
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
Richardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R., Alsina, M., Schlossman, R. L., Rajkumar, S. V., Desikan, K. R., Hideshima, T., et al. (2006) · Blood · doi:10.1182/blood-2006-04-015909 · Cited by 523
Self-citation
Combination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma
Rajkumar, S. V., Hayman, S., Gertz, M. A., Dispenzieri, A., Lacy, M. Q., Greipp, P. R., Geyer, S., Iturria, N., Fonseca, R., Lust, J. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.116 · Cited by 512
Self-citation

Flagged first, then by citations

Show all 13 references

Sorted by citations

Cancer-related inflammation
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Multiple Myeloma
Palumbo, A. P., & Anderson, K. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,382
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
Kumar, S. K., Dispenzieri, A. A., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Pandey, S., Kapoor, P., Dingli, D., Hayman, S. R., Leung, N., et al. (2013) · Leukemia · doi:10.1038/leu.2013.313 · Cited by 1,383
Self-citation
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332
Self-citation
Cardiovascular Complications of Cancer Therapy
Yeh, E. T. H., & Bickford, C. L. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.050 · Cited by 1,296
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Attal, M., Lauwers-Cances, V., Hulin, C., Leleu, X., Caillot, D., Escoffre, M., Arnulf, B., Macro, M., Belhadj, K., Garderet, L., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611750 · Cited by 1,257
Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
Mateos, M.-V., Hernández, M.-T., Giraldo, P., de la Rubia, J., de Arriba, F., Corral, L. L., Rosiñol, L., Paiva, B., Palomera, L., Bargay, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300439 · Cited by 1,171
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A. M., Hulin, C., Benboubker, L., Garderet, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114138 · Cited by 1,155
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
Rajkumar, S. V., Jacobus, S., Callander, N. S., Fonseca, R., Vesole, D. H., Williams, M. E., Abonour, R., Siegel, D. S., Katz, M., & Greipp, P. R. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70284-0 · Cited by 933
Self-citation
Multiple myeloma
van de Donk, N. W. C. J., Pawlyn, C., & Yong, K. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00135-5 · Cited by 935
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Moreau, P., Miguel, J. F. S., Sonneveld, P., Mateos, M., Zamagni, E., Avet‐Loiseau, H., Hájek, R., Dimopoulos, M. A., Ludwig, H., Einsele, H., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx096 · Cited by 901
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
Richardson, P. G., Weller, E., Lonial, S., Jakubowiak, A. J., Jagannath, S., Raje, N. S., Avigan, D. E., Xie, W., Ghobrial, I. M., Schlossman, R. L., et al. (2010) · Blood · doi:10.1182/blood-2010-02-268862 · Cited by 861
Self-citation
Multiple myeloma
Kyle, R. A., & Rajkumar, S. V. (2008) · Blood · doi:10.1182/blood-2007-10-078022 · Cited by 884
Self-citation
Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial
Sonneveld, P., Schmidt-Wolf, I. G. H., van der Holt, B., el Jarari, L., Bertsch, U., Salwender, H., Zweegman, S., Vellenga, E., Broyl, A., Blau, I. W., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.6820 · Cited by 824
Multiple Myeloma: Diagnosis and Treatment
Rajkumar, S. V., & Kumar, S. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.11.007 · Cited by 812
Self-citation
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
Miguel, J. F. S., Weisel, K. C., Moreau, P., Lacy, M. Q., Song, K., Delforge, M., Karlin, L., Goldschmidt, H., Banos, A., Oriol, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70380-2 · Cited by 806
Self-citation
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402551 · Cited by 793
Self-citation
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
Miguel, J. F. S., Hungria, V., Yoon, S., Beksaç, M., Dimopoulos, M. A., Elghandour, A., Wiktor-Jędrzejczak, W., Günther, A., Nakorn, T. N., Siritanaratkul, N., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70440-1 · Cited by 801
Self-citation
Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
Palumbo, A. P., Hájek, R., Delforge, M., Kropff, M. H., Petrucci, M. T., Catalano, J. V., Gisslinger, H., Wiktor-Jędrzejczak, W., Zodelava, M., Weisel, K. C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112704 · Cited by 748
Self-citation
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
Kumar, S. K., Lee, J. H., Lahuerta, J. J., Morgan, G., Richardson, P. G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., et al. (2012) · Leukemia · doi:10.1038/leu.2011.196 · Cited by 721
Self-citation
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
McCarthy, P. L., Holstein, S. A., Petrucci, M. T., Richardson, P. G., Hulin, C., Tosi, P., Bringhen, S., Musto, P., Anderson, K. C., Caillot, D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.6679 · Cited by 698
Self-citation
Multiple myeloma
Raab, M. S., Podar, K., Breitkreutz, I., Richardson, P. G. G., & Anderson, K. C. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60221-x · Cited by 713
Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies
Chen, M., Zhao, Y., Xu, C., Wang, X., Zhang, X., & Mao, B. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3284-y · Cited by 647
Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines
Kumar, S. K., Mikhael, J. R., Buadi, F. K., Dingli, D., Dispenzieri, A., Fonseca, R., Gertz, M. A., Greipp, P. R., Hayman, S. R., Kyle, R. A., et al. (2009) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0603 · Cited by 628
Self-citation
Chemotherapy-induced peripheral neurotoxicity (CIPN): An update
Argyriou, A. A., Bruna, J., Marmiroli, P., & Cavaletti, G. (2011) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.04.012 · Cited by 595
Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013
Mikhael, J. R., Dingli, D., Roy, V., Reeder, C. B., Buadi, F. K., Hayman, S. R., Dispenzieri, A. A., Fonseca, R., Sher, T., Kyle, R. A., et al. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.01.019 · Cited by 504
Self-citation
Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients
Varettoni, M., Corso, A., Pica, G.-M., Mangiacavalli, S., Pascutto, C., & Lazzarino, M. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp329 · Cited by 489
Classification of current anticancer immunotherapies
Galluzzi, L., Vacchelli, E., Pedro, J. M. B., Buqué, A., Senovilla, L., Baracco, E. E., Bloy, N., Castoldi, F., Abastado, J., Agostinis, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2998 · Cited by 481
Mechanism of action of lenalidomide in hematological malignancies
Kotla, V., Goel, S., Nischal, S., Heuck, C. J., Vivek, K., Das, B. C., & Verma, A. K. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-36 · Cited by 476
Multiple myeloma: 2016 update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2016) · American Journal of Hematology · doi:10.1002/ajh.24402 · Cited by 466
Self-citation
Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial
Palumbo, A., Bringhen, S., Rossi, D., Cavalli, M., Larocca, A., Ria, R., Offidani, M., Patriarca, F., Nozzoli, C., Guglielmelli, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.8216 · Cited by 423
International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation
Palumbo, A. P., Rajkumar, S. V., Miguel, J. F. S., Larocca, A., Niesvizky, R., Morgan, G. J., Landgren, O., Hájek, R., Einsele, H., Anderson, K. C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.48.7934 · Cited by 397
Self-citation
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
Richardson, P. G., Siegel, D. S., Vij, R., Hofmeister, C. C., Baz, R., Jagannath, S., Chen, C., Lonial, S., Jakubowiak, A., Bahlis, N., et al. (2014) · Blood · doi:10.1182/blood-2013-11-538835 · Cited by 381
Self-citation
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma
Dimopoulos, M. A., Chen, C. L., Spencer, A. G., Niesvizky, R., Attal, M., Stadtmauer, E. A., Petrucci, M. T., Yu, Z., Olesnyckyj, M., Zeldis, J. B., et al. (2009) · Leukemia · doi:10.1038/leu.2009.147 · Cited by 366
Self-citation
Monoclonal antibodies targeting CD 38 in hematological malignancies and beyond
van de Donk, N. W. C. J., Janmaat, M. L., Mutis, T., Lammerts van Bueren, J. J., Ahmadi, T., Sasser, A. K., Lokhorst, H. M., & Parren, P. W. H. I. (2016) · Immunological Reviews · doi:10.1111/imr.12389 · Cited by 353
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)
Palumbo, A. P., Bringhen, S., Ludwig, H., Dimopoulos, M. A., Bladé, J., Mateos, M., Rosiñol, L., Boccadoro, M., Cavo, M., Lokhorst, H. M., et al. (2011) · Blood · doi:10.1182/blood-2011-06-358812 · Cited by 358
Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study
Goy, A. H., Sinha, R., Williams, M. E., Beşışık, S. K., Drach, J. W., Ramchandren, R., Zhang, L., Cicero, S., Fu, T., & Witzig, T. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.2835 · Cited by 358
Infections in Patients with Multiple Myeloma in the Era of High‐Dose Therapy and Novel Agents
Nucci, M., & Anaissie, E. (2009) · Clinical Infectious Diseases · doi:10.1086/605664 · Cited by 347
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies
Siegel, D. S. D., Martin, T. G., Nooka, A., Harvey, R. D., Vij, R., Niesvizky, R., Badros, A. Z., Jagannath, S., McCulloch, L. M., Rajangam, K. L., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.089334 · Cited by 347
Self-citation
A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
Zonder, J. A., Mohrbacher, A. F., Singhal, S., van Rhee, F., Bensinger, W. I., Ding, H., Fry, J., Afar, D. E. H., & Singhal, A. K. (2012) · Blood · doi:10.1182/blood-2011-06-360552 · Cited by 342
Bone marrow microenvironment and the identification of new targets for myeloma therapy
Podar, K., Chauhan, D., & Anderson, K. C. (2008) · Leukemia · doi:10.1038/leu.2008.259 · Cited by 341
Cytokines as a key component of cancer-related inflammation
Germano, G., Allavena, P., & Mantovani, A. (2008) · Cytokine · doi:10.1016/j.cyto.2008.07.014 · Cited by 334
Multiple myeloma: patient outcomes in real‐world practice
Yong, K., Delforge, M., Driessen, C., Fink, L., Flinois, A., Gonzalez‐McQuire, S., Safaei, R., Karlin, L., Mateos, M., Raab, M. S., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14213 · Cited by 326
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
Lacy, M. Q., Hayman, S. R., Gertz, M. A., Dispenzieri, A., Buadi, F., Kumar, S., Greipp, P. R., Lust, J. A., Russell, S. J., Dingli, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6802 · Cited by 317
Self-citation
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity
McMillin, D. W., Delmore, J. E., Weisberg, E., Negri, J. M., Geer, D. C., Klippel, S., Mitsiades, N., Schlossman, R. L., Munshi, N. C., Kung, A. L., et al. (2010) · Nature Medicine · doi:10.1038/nm.2112 · Cited by 324
Molecular mechanisms underlying chronic inflammation-associated cancers
Wu, Y., Antony, S., Meitzler, J. L., & Doroshow, J. H. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.08.014 · Cited by 312
Guidelines for the diagnosis and management of multiple myeloma 2011
Bird, J. M., Owen, R. G., D’Sa, S., Snowden, J. A., Pratt, G., Ashcroft, J., Yong, K., Cook, G., Feyler, S., Davies, F. E., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08573.x · Cited by 309
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline
Richardson, P. G. G., Sonneveld, P., Schuster, M. W., Stadtmauer, E. A., Facon, T. T. F., Harousseau, J., Ben‐Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D. E., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07573.x · Cited by 305
Self-citation
Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
Lonial, S., Vij, R., Harousseau, J., Facon, T. T. F., Moreau, P., Mazumder, A., Kaufman, J. L., Leleu, X. P., Tsao, L. C., Westland, C. E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.2649 · Cited by 296
Self-citation
PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma
Richardson, P. G. G., Schlossman, R. L., Alsina, M., Weber, D. M., Coutre, S. E., Gasparetto, C., Mukhopadhyay, S., Ondovik, M. S., Khan, M. M. H., Paley, C. S., et al. (2013) · Blood · doi:10.1182/blood-2013-01-481325 · Cited by 291
Self-citation
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide
Larocca, A., Cavallo, F., Bringhen, S., Raimondo, F. D., Falanga, A., Evangelista, A., Cavalli, M. M., Stanevsky, A., Corradini, P., Pezzatti, S., et al. (2011) · Blood · doi:10.1182/blood-2011-03-344333 · Cited by 292
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma
Facon, T., Dimopoulos, M. A., Dispenzieri, A., Catalano, J. V., Belch, A., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N. J., et al. (2018) · Blood · doi:10.1182/blood-2017-07-795047 · Cited by 271
Self-citation
Panobinostat for the Treatment of Multiple Myeloma
Laubach, J. P., Moreau, P., Miguel, J. F. S., & Richardson, P. G. G. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0530 · Cited by 273
Pegylated Liposomal Doxorubicin: A Review of its use in Metastatic Breast Cancer, Ovarian Cancer, Multiple Myeloma and AIDS-Related Kaposiʼs Sarcoma
Duggan, S. T., & Keating, G. M. (2011) · Drugs · doi:10.2165/11207510-000000000-00000 · Cited by 234
Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Witzig, T. E., Wiernik, P. H., Moore, T. D., Reeder, C. B., Cole, C. E., Justice, G. R., Kaplan, H. G., Voralia, M., PIETRONIGRO, D. D., Takeshita, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1169 · Cited by 258
Self-citation
Management of relapsed multiple myeloma: Recommendations of the International Myeloma Working Group
Laubach, J., Garderet, L., Mahindra, A., Gahrton, G., Caers, J., Sezer, O., Voorhees, P., Leleu, X., Johnsen, H. E., Streetly, M., et al. (2016) · Leukemia · doi:10.1038/leu.2015.356 · Cited by 258
Self-citation
Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience
Holstein, S. A., & McCarthy, P. L. (2017) · Drugs · doi:10.1007/s40265-017-0689-1 · Cited by 263
Management of treatment-emergent peripheral neuropathy in multiple myeloma
Richardson, P. G. G., Delforge, M., Beksaç, M., Wen, P. Y., Jongen, J. L. M., Sezer, O., Terpos, E., Munshi, N. C., Palumbo, A. P., Rajkumar, S. V., et al. (2011) · Leukemia · doi:10.1038/leu.2011.346 · Cited by 253
Self-citation
Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma
Habermann, T. M., Lossos, I. S., Justice, G. R., Vose, J. M., Wiernik, P. H., McBride, K., Wride, K., Ervin-Haynes, A. L., Takeshita, K., PIETRONIGRO, D. D., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07626.x · Cited by 248
Self-citation
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Moreau, P., Miguel, J. F. S., Ludwig, H., Schouten, H. C., Mohty, M., Dimopoulos, M. A., & Dreyling, M. H. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt297 · Cited by 242
Venous Thromboembolic Disease
Streiff, M. B., Bockenstedt, P. L., Cataland, S. R., Chesney, C. M., Eby, C., Fanikos, J. R., Fogarty, P. F., Gao, S., García‐Aguilar, J., Goldhaber, S. Z., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0062 · Cited by 238
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)
Ocio, E. M., Richardson, P. G. G., Rajkumar, S. V., Palumbo, A. P., Mateos, M., Orlowski, R. Z., Kumar, S. K., Usmani, S. Z., Roodman, D., Niesvizky, R., et al. (2013) · Leukemia · doi:10.1038/leu.2013.350 · Cited by 239
Self-citation
Multiple Myeloma
Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Chanan-Khan, A. A., Cohen, A. D., Devine, S. M., Djulbegović, B., Gasparetto, C., Huff, C. A., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0061 · Cited by 227
Self-citation
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
Shah, J. J., Stadtmauer, E. A., Abonour, R., Cohen, A. D., Bensinger, W., Gasparetto, C., Kaufman, J. L., Lentzsch, S., Vogl, D. T., Gomes, C. L., et al. (2015) · Blood · doi:10.1182/blood-2015-05-643320 · Cited by 225
Self-citation
The role of complete response in multiple myeloma
Harousseau, J., Attal, M., & Avet‐Loiseau, H. (2009) · Blood · doi:10.1182/blood-2009-03-201053 · Cited by 222
Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues
Delforge, M., Bladé, J., Dimopoulos, M. A., Facon, T. T. F., Kropff, M. H., Ludwig, H., Palumbo, A. P., Damme, P. V., Miguel, J. F. S., & Sonneveld, P. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70068-1 · Cited by 223
The novel mechanism of lenalidomide activity
Fink, E. C., & Ebert, B. L. (2015) · Blood · doi:10.1182/blood-2015-07-567958 · Cited by 213
Multiple myeloma: 2014 Update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2014) · American Journal of Hematology · doi:10.1002/ajh.23810 · Cited by 215
Self-citation
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma
Breitkreutz, I., Raab, M. S., Vallet, S., Hideshima, T., Raje, N. S., Mitsiades, C. S., Chauhan, D., Okawa, Y., Munshi, N. C., Richardson, P. G. G., et al. (2008) · Leukemia · doi:10.1038/leu.2008.174 · Cited by 209
Guidelines for supportive care in multiple myeloma 2011
Snowden, J. A., Ahmedzai, S. H., Ashcroft, J., D’Sa, S., Littlewood, T. J., Low, E., Lucraft, H. H., Maclean, R., Feyler, S., Pratt, G., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08574.x · Cited by 208
Latest advances and current challenges in the treatment of multiple myeloma
Mahindra, A. K., Laubach, J. P., Raje, N. S., Munshi, N. C., Richardson, P. G. G., & Anderson, K. C. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.15 · Cited by 204
Chasing molecular glue degraders: screening approaches
Domostegui, A., Nieto-Barrado, L., Perez-Lopez, C., & Mayor-Ruiz, C. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00197g · Cited by 200
Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta‐analysis
Carrier, M., Gal, G. L., Tay, J., Wu, C., & Lee, A. Y. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04215.x · Cited by 195
Thrombotic Events in Patients With Cancer Receiving Antiangiogenesis Agents
Zangari, M., Fink, L. M., Elice, F., Zhan, F., Adcock, D. M., & Tricot, G. J. K. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.3875 · Cited by 195
Current treatment landscape for relapsed and/or refractory multiple myeloma
Dimopoulos, M. A., Richardson, P. G. G., Moreau, P., & Anderson, K. C. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.200 · Cited by 197
Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)
Zonder, J. A., Crowley, J. J., Hussein, M. A., Bolejack, V., Moore, D. F., Whittenberger, B. F., Abidi, M. H., Durie, B. G. M., & Barlogie, B. (2010) · Blood · doi:10.1182/blood-2010-08-303487 · Cited by 196
The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development
Rehman, W., Arfons, L. M., & Lazarus, H. M. (2011) · Therapeutic Advances in Hematology · doi:10.1177/2040620711413165 · Cited by 207
Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis
Tefferi, A., Verstovšek, S., Barosi, G., Passamonti, F., Roboz, G. J., Gisslinger, H., PAQUETTE, R. L., Cervantes, F., Rivera, C. E., Deeg, H. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.7356 · Cited by 196
Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents
Chanan-Khan, A. A., & Giralt, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4250 · Cited by 196
Self-citation
Venous Thromboembolism in the Hematologic Malignancies
Falanga, A., & Marchetti, M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8197 · Cited by 196
Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial
Mateos, M., Hernández, M.-T., Giraldo, P., de la Rubia, J., de Arriba, F., López‐Corral, L., Rosiñol, L., Paiva, B., Palomera, L., Bargay, J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30124-3 · Cited by 195
Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Garderet, L., Iacobelli, S., Moreau, P., Dib, M., Lafon, I., Niederwieser, D. W., Masszi, T., Fontan, J., Michallet, M., Gratwohl, A. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.4918 · Cited by 188
Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13
Reece, D. E., Song, K., Fu, T., Roland, B., Chang, H., Horsman, D. E., Mansoor, A., Chen, C. I., Masih‐Khan, E., Trieu, Y., et al. (2009) · Blood · doi:10.1182/blood-2008-12-193458 · Cited by 183
Self-citation
Lenalidomide downregulates the cell survival factor, interferon regulatory factor‐4, providing a potential mechanistic link for predicting response
Lopez‐Girona, A., Heintel, D., Zhang, L., Mendy, D., Gaidarova, S., Brady, H. A., Bartlett, J. B., Schafer, P. H., Schreder, M., Bolomsky, A., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08689.x · Cited by 184
Cancer Therapy–Associated Thrombosis
Grover, S. P., Hisada, Y., Kasthuri, R. S., Reeves, B., & Mackman, N. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.314378 · Cited by 192
A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma
Benson, D. M., Cohen, A. D., Jagannath, S., Munshi, N. C., Spitzer, G., Hofmeister, C. C., Efebera, Y. A., André, P., Zerbib, R. A., & Caligiuri, M. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0304 · Cited by 184
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma
Richardson, P. G. G., Xie, W., Jagannath, S., Jakubowiak, A. J., Lonial, S., Raje, N. S., Alsina, M., Ghobrial, I. M., Schlossman, R. L., Munshi, N. C., et al. (2014) · Blood · doi:10.1182/blood-2013-07-517276 · Cited by 181
Self-citation
Proteasome inhibitors in the treatment of multiple myeloma
Shah, J. J., & Orlowski, R. Z. (2009) · Leukemia · doi:10.1038/leu.2009.173 · Cited by 179
Therapeutic targeting of microenvironmental interactions in leukemia: Mechanisms and approaches
Konopleva, M. Y., Tabe, Y., Zeng, Z., & Andreeff, M. (2009) · Drug Resistance Updates · doi:10.1016/j.drup.2009.06.001 · Cited by 182
Novel agents in the treatment of multiple myeloma: a review about the future
Naymagon, L., & Abdul‐Hay, M. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0282-1 · Cited by 180
Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure
Wang, M., Dimopoulos, M. A., Chen, C., Cibeira, M. T., Attal, M., Spencer, A., Rajkumar, S. V., Yu, Z., Olesnyckyj, M., Zeldis, J. B., et al. (2008) · Blood · doi:10.1182/blood-2008-02-141614 · Cited by 176
Self-citation
Treatment of relapsed and refractory multiple myeloma
Sonneveld, P., & Broijl, A. (2016) · Haematologica · doi:10.3324/haematol.2015.129189 · Cited by 181
Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism
Escoubet‐Lozach, L., Lin, I.-L., Jensen-Pergakes, K., Brady, H. A., Gandhi, A. K., Schafer, P. H., Muller, G. W., Worland, P. J., Chan, K. W. H., & Verhelle, D. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4898 · Cited by 173
Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients
Palumbo, A. P., Gay, F., Falco, P., Crippa, C., Montefusco, V., Patriarca, F. F., Rossini, F., Caltagirone, S., Benevolo, G., Pescosta, N., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.7561 · Cited by 175
Impairment of Filgrastim-Induced Stem Cell Mobilization after Prior Lenalidomide in Patients with Multiple Myeloma
Popat, U., Saliba, R. M., Thandi, R. S., Hosing, C. M., Qazilbash, M. H., Anderlini, P. N., Shpall, E. J., McMannis, J. D., Korbling, M. J., Alousi, A. M., et al. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2009.02.011 · Cited by 168
Self-citation
A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma
Martin, T. G., Baz, R., Benson, D. M., Lendvai, N. K., Wolf, J. L., Münster, P. N., Lesokhin, A. M., Wack, C., Charpentier, E., Campana, F., et al. (2017) · Blood · doi:10.1182/blood-2016-09-740787 · Cited by 169
Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations
Mohty, B., Cheikh, J. E., Yakoub‐Agha, I., Moreau, P., Harousseau, J., & Mohty, M. (2010) · Haematologica · doi:10.3324/haematol.2009.012674 · Cited by 172
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma
Giralt, S., Garderet, L., Durie, B. G. M., Cook, G., Gahrton, G., Bruno, B., Hari, P., Lokhorst, H. M., McCarthy, P., Krishnan, A. Y., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.09.016 · Cited by 170
Self-citation
Achievement of at Least Very Good Partial Response Is a Simple and Robust Prognostic Factor in Patients With Multiple Myeloma Treated With High-Dose Therapy: Long-Term Analysis of the IFM 99-02 and 99-04 Trials
Harousseau, J., Avet‐Loiseau, H., Attal, M., Guérin‐Charbonnel, C., Garban, F., Hulin, C., Michallet, M., Facon, T. T. F., Garderet, L., Marit, G., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1060 · Cited by 166

Authors: Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., Lonial, S., Yu, Z., Patin, J., Olesnyckyj, M., Zeldis, J. B., & Knight, R. D.
Affiliations: The University of Texas MD Anderson Cancer Center (US)
Princess Margaret Cancer Centre (CA)
Cross Cancer Institute (CA)
University of Pennsylvania (US)
Hackensack University Medical Center (US)
Sidney Kimmel Comprehensive Cancer Center (US)
Mayo Clinic (US)
Roswell Park Comprehensive Cancer Center (US)
Emory University (US)
Celgene (United States) (US)
ORCID: Chen, Christine
Wang, Michael
Belch, Andrew
Stadtmauer, Edward A.
Siegel, David
Borrello, Ivan
Rajkumar, S. Vincent
Chanan-Khan, Asher Alban
Lonial, Sagar
Zeldis, Jerome B.
Knight, Robert D.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2007-11-22
Volume: 357
Issue: 21
Pages: 2133-2142
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa070596
OpenAlex: W2021954218
Cited by: 1,233
References: 13
Citations by year: 2026: 5 · 2025: 10 · 2024: 14 · 2023: 36 · 2022: 41 · 2021: 35 · 2020: 31 · 2019: 46 · 2018: 57 · 2017: 69 · 2016: 83 · 2015: 74 · 2014: 77 · 2013: 126 · 2012: 111
FWCI: 62.27
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
Health Sciences › Medicine › Oncology › Bone health and treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Keywords: lenalidomide, dexamethasone, relapsed multiple myeloma, refractory multiple myeloma, immunomodulators, combination chemotherapy, complete response, time to progression, overall survival, neutropenia, venous thromboembolism, adverse events, North America, thalidomide analogues, treatment efficacy and safety
MeSH terms: Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Double-Blind Method, Female, Glucocorticoids, Humans, Immunologic Factors, Male, Middle Aged, Multiple Myeloma, Recurrence, Thalidomide, Survival Analysis, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks